Included in the formulation
АТХ:C.07.A.B.13 Talinolol
Pharmacodynamics:Selective β1-blocker, which does not have internal sympathomimetic activity.Has antihypertensive, antiarrhythmic, antianginal action. In therapeutic doses does not affect the tone of peripheral arteries.
Reduces the effect of catecholamines on the heart muscle, thereby reducing the heart rate, minute and shock volumes of blood within 24 hours.
Eliminates the effects of arrhythmogenic factors: tachycardia, arterial hypertension, elevated cAMP content.
Antianginal action is due to a decrease in myocardial oxygen demand with prolonged diastole and improved perfusion of the heart muscle.
Pharmacokinetics:After oral administration, up to 70% is absorbed in the gastrointestinal tract. The maximum concentration in blood plasma is achieved through 1.7-4 h. The connection with plasma proteins is 50%.
Poorly penetrates the blood-brain barrier, penetrates the placenta. Metabolism in the liver.
The half-life is 7.8-18.2 hours. Elimination by the kidneys.
Indications:It is used for relief of hypertensive crises, for treatment neurocirculatory dystonia according to the hypertonic type, ischemic heart disease, with any form of angina pectoris.Used for arrhythmias: from single extrasystoles to atrial flutter.
IX.I30-I52.I49.1 Premature depolarization of the atria
IX.I30-I52.I49.3 Premature depolarization of the ventricles
IX.I30-I52.I51.8 Other inaccurately marked heart diseases
IX.I10-I15.I15 Secondary Hypertension
IX.I10-I15.I10 Essential [primary] hypertension
IX.I20-I25.I20 Angina pectoris [angina pectoris]
IX.I20-I25.I21 Acute myocardial infarction
IX.I20-I25.I25 Chronic ischemic heart disease
IX.I30-I52.I47.9 Paroxysmal tachycardia, unspecified
IX.I30-I52.I48 Atrial fibrillation and flutter
IX.I30-I52.I50.9 Heart failure, unspecified
Contraindications:Cardiogenic shock, atrioventricular blockade of II-III degree, bradycardia, chronic cardiac insufficiency, resistant to the action of cardiac glycosides, bronchial asthma, renal and hepatic insufficiency, individual intolerance, children under 18.
Carefully:Metabolic acidosis, pheochromocytoma, stenocardia prinzmetala, psoriasis, hypersensitivity.
Pregnancy and lactation:Recommendations for FDA - Category C. It is used for life indications during pregnancy in those cases when the intended benefit exceeds the risk for the fetus. Contraindicated in lactation.
Dosing and Administration:Inside 1-2 times a day for 30-40 minutes before meals for 50 mg, if necessary, the dose increases to 300 mg per day.
Intravenously struino slowly or drip, 10-20 mg, if necessary, repeated administration after 10 minutes.
The highest daily dose: 600 mg for oral administration, 60 mg for parenteral administration.
The highest single dose: 300 mg for oral administration, 50 mg for parenteral administration.
Side effects:central nervous system: dizziness, insomnia, asthenia, hallucinations.
Respiratory system: shortness of breath, rarely - bronchospasm
The cardiovascular system: bradycardia, atrioventricular blockade, cold extremities.
Blood System: neutropenia, thrombocytopenia.
Sense organs: "dry eye syndrome", transient visual impairment.
Gastrointestinal tract: indigestion, diarrhea, or constipation.
Reproductive system: lowering the potency.
Dermatological reactions: Hyperhidrosis.
Allergic reactions.
Overdose:Pronounced bradycardia, arterial hypotension.
Treatment: intravenously 1-2 mg atropine, 2.5 μg / kg dobutamine, intravenously bolus 10 mg glucagon, intravenously drip 10-20 μg isoprenaline at a rate of not more than 5 μg / min.
Interaction:Negative dromo-, foreign, chromotropic influences are intensified with simultaneous admission with amiodarone, anesthetics, antiarrhythmics, digoxin, diltiazem, verapamil.
Increases the bioavailability of talinolol together with cimetidine.
Special instructions:When giving general anesthesia to patients receiving talinolol, means with minimal inotropic action are used. Before surgery, it is recommended to stop taking the medication 48 hours before the operation.